GLP-1 compositions and uses thereof
By adding appropriate amount of phenol and control composition ingredients to the liquid drug of GLP-1 peptide, the problem of insufficient stability is solved, and high stability and effectiveness under different storage conditions are achieved. It is suitable for diabetes and obesity. treat.
Patent Information
- Application Number
- CN202411246465.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-08-24
- Filing Date
- 2018-08-24
- Publication Date
- 2024-11-08
AI Technical Summary
GLP-1 peptide is prone to stability problems in liquid solutions, especially lack of physical and chemical stability, which affects the effectiveness of its drug application.
By adding no more than 0.01% phenol to the liquid pharmaceutical composition and controlling the concentration, pH value and auxiliary components of the composition, a stable liquid composition containing GLP-1 peptide is formed for parenteral administration, especially subcutaneous administration Dosing, combining the use of durable pen and prefilled pen injection devices.
It significantly improves the chemical and physical stability of GLP-1 peptides, ensures at least 80% covalent bond integrity and does not form aggregates under different storage conditions, extends the effectiveness of the drug, and is suitable for the treatment of diabetes and obesity.
Smart Images

Figure BDA0005030912860000121 
Figure BDA0005030912860000131 
Figure BDA0005030912860000132
Abstract
Description
[0001] This application is a divisional application of the Chinese invention patent application with application date of August 24, 2018, application number 201880054209.2, and invention name “GLP-1 compositions and uses thereof”.
[0002] The present invention relates to the field of pharmaceutical compositions comprising the GLP-1 peptide semaglutide. Background of the Invention
[0004] It is known that GLP-1 peptides are susceptible to stability deficiencies, such as physical stability deficiencies, in liquid solutions. Therefore, there is a need for liquid pharmaceutical compositions comprising GLP-1 peptides with improved stability. This improved stability may be physical stability and / or chemical stability. Summary of the invention
[0005] In some embodiments, the invention relates to a liquid pharmaceutical composition comprising semaglutide and no more than 0.01% (w / w) phenol. In some embodiments, the invention relates to a kit comprising a pharmaceutical composition as defined herein. In some embodiments, the invention relates to a pharmaceutical composition as defined herein for medical use.
[0006] The present invention also relates to the following embodiments:
[0007] 1. A liquid pharmaceutical composition comprising semaglutide and no more than 0.01% (w / w) phenol, wherein the composition
[0008] a) for parenteral administration;
[0009] b) is an aqueous solution comprising at least 60% w / w water; or
[0010] c) further comprises one or more pharmaceutically acceptable excipients selected from a buffer or an isotonicity agent.
[0011] 2. The composition of embodiment 1, wherein the composition does not contain phenol.
[0012] 3. A composition according to any one of the preceding embodiments, wherein the composition is an aqueous solution comprising at least 60% w / w water.
[0013] 4. The composition according to any one of the preceding embodiments, wherein the concentration of semaglutide is 0.5-10 mg / ml or 0.01-5 mg / ml of the composition.
[0014] 5. A composition according to any one of the preceding embodiments, wherein the composition comprises one or more pharmaceutically acceptable excipients.
[0015] 6. A composition according to embodiment 5, wherein the one or more pharmaceutically acceptable excipients are selected from a buffer or an isotonic agent.
[0016] 7. A composition according to any one of the preceding embodiments, wherein the composition does not contain a preservative.
[0017] 8. A composition according to any one of the preceding embodiments, wherein the pH of the composition is in the range of 6.0-10.0, such as pH 7.0-7.8.
[0018] 9. A composition according to any one of the preceding embodiments, wherein the composition is for parenteral administration.
[0019] 10. The composition of embodiment 9, wherein the parenteral administration is subcutaneous administration.
[0020] 11. A kit comprising a liquid pharmaceutical composition comprising semaglutide and no more than 0.01% (w / w) phenol and instructions for use.
[0021] 12. A kit comprising a liquid pharmaceutical composition comprising semaglutide and no more than 0.01% (w / w) phenol and an injection device for administering the composition to a subject, wherein the injection device is selected from a durable pen and a prefilled pen injection device.
[0022] 13. The kit according to embodiment 11 or 12, wherein the pharmaceutical composition is as defined in any one of embodiments 1-10.
[0023] 14. A pharmaceutical composition as described in any one of the preceding embodiments for medical use.
[0024] 15. The pharmaceutical composition according to any one of the preceding embodiments, for use in treating diabetes or obesity. DETAILED DESCRIPTION OF THE INVENTION
[0026] The present invention relates to a liquid pharmaceutical composition comprising the GLP-1 peptide semaglutide and no more than 0.01% (w / w) of phenol. Surprisingly, the inventors have found that such compositions have improved chemical and / or physical stability. In some embodiments, the composition does not comprise phenol. In some embodiments, the composition comprises 0.01-10 mg / ml semaglutide. In some embodiments, the pH of the composition is in the range of 6.0-10.0, such as pH 7.0-7.8.
[0027] In some embodiments, the composition of the present invention is a liquid pharmaceutical composition comprising semaglutide and no more than 0.01% (w / w) phenol, wherein the composition
[0028] a. For parenteral administration;
[0029] b. is an aqueous solution comprising at least 60% w / w water; or
[0030] c. further comprising one or more pharmaceutically acceptable excipients selected from a buffer or an isotonicity agent.
[0031] In some embodiments, the composition of the present invention is a liquid pharmaceutical composition comprising semaglutide, no more than 0.01% (w / w) phenol and optionally one or more pharmaceutically acceptable excipients, wherein the formulation is for parenteral administration, such as subcutaneous administration.
[0032] In some embodiments, the composition of the present invention is a liquid pharmaceutical composition comprising semaglutide, no more than 0.01% (w / w) phenol, at least 60% w / w water, and optionally one or more pharmaceutically acceptable excipients.
[0033] In some embodiments, the term "stability" as used herein refers to the stability of semaglutide in a liquid pharmaceutical composition. In some embodiments, stability is the chemical stability of the GLP-1 peptide (e.g., as determined by HPLC as in Assay (I) herein), and optionally the physical stability of the GLP-1 peptide (e.g., as determined by Thioflavin T as in Assay (II) herein).
[0034] In some embodiments, the term "chemical stability" as used herein for semaglutide means that the covalent bonds of the semaglutide compound are substantially intact. In some embodiments, the chemical stability of the GLP-1 peptide is determined by HPLC assay, such as assay (I) herein. In some embodiments, if at least 80% (w / v) of the covalent bonds in the GLP-1 peptide remain intact after storage for 3 months at 25°C, the composition is chemically stable. In some embodiments, the chemical stability of semaglutide is determined by assay (IV) herein.
[0035] In some embodiments, the term "physical stability" as used herein for semaglutide means that semaglutide does not substantially form aggregates, for example, does not substantially form aggregates in the form of fibrils. In some embodiments, physical stability is determined by a Thioflavin T assay, such as assay (II) herein.
[0036] In some embodiments, the composition of the present invention is a stable pharmaceutical composition. When used herein, the term "stable pharmaceutical composition" refers to a pharmaceutical composition comprising a GLP-1 peptide, such as a solution or suspension, which contains at least 80% (w / v) of the GLP-1 peptide after storage (e.g., after static storage for 3 months at 25 ° C). The storage conditions for the stability test can be 2-8 ° C, such as 5 ° C, or at least 2.5 years at 5 ° C. Alternatively, the storage conditions for the stability test can be at least 4 weeks, such as 6 weeks or 3 months, optionally at 30 ° C. The storage conditions of the stable pharmaceutical composition may be 1 year or 2 years at 5 ° C. The storage conditions of the stable pharmaceutical composition may be 3 years at 5 ° C. Alternatively, the storage conditions may be 24 hours or 1 week at 25 ° C. In another alternative, the storage conditions may be two months at room temperature, such as up to two months.
[0037] In some embodiments, the chemical stability of the GLP-1 peptide requires that at least 80% (w / v), such as at least 90% (w / v) or at least 95% (w / v) of the GLP-1 peptide retain its covalent bonds intact at the end of the storage period. In some embodiments, the chemical stability of the GLP-1 peptide requires that at least 95% (w / v), such as at least 97% (w / v) or at least 99% (w / v) of the GLP-1 peptide retain its covalent bonds intact at the end of the storage period.
[0038] The compositions of the present invention comprise no more than 0.01% (w / w) phenol. In some embodiments, the composition comprises substantially no phenol.
[0039] Pharmaceutical composition
[0040] The terms "pharmaceutical composition" and "composition" are used interchangeably herein to refer to a pharmaceutical composition suitable for administration to a subject in need thereof.
[0041] In some embodiments, the composition comprises 0.01-100mg / ml semaglutide. In some embodiments, the composition comprises 0.1-50mg / ml, such as 0.5-25mg / ml or 1-15mg / ml semaglutide. In some embodiments, the composition comprises 0.1-10mg / ml, such as 0.5-5mg / ml or 1-2mg / ml semaglutide. In some embodiments, the composition comprises 0.01-10mg / ml, such as 0.01-5mg / ml semaglutide. In some embodiments, the composition comprises no more than 9mg / ml, such as no more than 8mg / ml or no more than 7mg / ml semaglutide. In some embodiments, the composition comprises no more than 6mg / ml, such as no more than 5mg / ml or no more than 4mg / ml semaglutide. In some embodiments, the composition comprises no more than 3mg / ml, such as no more than 2mg / ml or no more than 1mg / ml semaglutide. In some embodiments, the composition comprises at least 0.01 mg / ml, such as at least 0.02 mg / ml or at least 0.05 mg / ml of semaglutide. In some embodiments, the composition comprises 1.34 mg / ml semaglutide.
[0042] In some embodiments, the pH of the composition of the invention is in the range of 3-10, such as pH 6-10 or 6- 9. In some embodiments, the pH of the composition of the invention is in the range of pH 6.5-8.5, such as pH 7.0-7.8.
[0043] In some embodiments, the compositions of the present invention comprise one or more pharmaceutically acceptable excipients.
[0044] In some embodiments, the compositions of the invention comprise an isotonic agent, such as propylene glycol. In some embodiments, the isotonic agent is propylene glycol or sodium chloride.
[0045] In some embodiments, the composition of the present invention comprises a buffer, such as phosphate buffer, TRIS, citrate, or does not comprise a buffer. In some embodiments, the phosphate buffer is a sodium phosphate buffer, such as disodium hydrogen phosphate.
[0046] In some embodiments, the compositions of the present invention do not include preservatives.
[0047] The composition of the present invention is in the form of a liquid pharmaceutical composition. In some embodiments, the liquid pharmaceutical composition is a solution or a suspension. In some embodiments, the composition of the present invention is in the form of a solution, such as an aqueous solution. In some embodiments, the term "aqueous solution" as used herein refers to a solution comprising at least 60% w / w of water. In some embodiments, the aqueous solution comprises 60-99% w / w of water. In some embodiments, the aqueous solution comprises at least 75% w / w of water, such as at least 80% w / w of water or at least 85% w / w of water. In some embodiments, the aqueous solution comprises at least 90% w / w of water, such as at least 92% w / w of water or at least 94% w / w of water.
[0048] Semaglutide
[0049] The GLP-1 peptide semaglutide can be prepared as described in Example 4 of WO2006 / 097537. Semaglutide is also known as N 6.26 -{18-[N-(17-carboxyheptadecanyl)-L-γ-glutamyl]-10-oxo-3,6,12,15-tetraoxa-9,18-diazaoctadecanoyl}-[8-(2-amino-2-propionic acid), 34-L-arginine] human glucagon-like peptide 1 (7-37), see WHO Drug Information Vol.24, No.1, 2010. In some embodiments, semaglutide may be present in the composition in its fully or partially ionized form; for example, one or more carboxylic acid groups (-COOH) may be deprotonated to carboxylate groups (-COO - ), and / or one or more amino groups (-NH2) may be protonated to -NH3 + In some embodiments, semaglutide is added to the composition in the form of a salt.
[0050] Dosage and kit
[0051] The composition of the present invention is for parenteral administration. In some embodiments, the composition is for subcutaneous administration.
[0052] In some embodiments, the compositions of the invention are for administration once a week. In some embodiments, the compositions of the invention are for administration once a day, once every two days, or once every three days.
[0053] In some embodiments, the invention relates to a kit comprising a pharmaceutical composition as defined herein and instructions for use. In some embodiments, the instructions for use comprise a package insert of the pharmaceutical.
[0054] In some embodiments, the present invention relates to a kit comprising a pharmaceutical composition as defined herein and an injection device. In some embodiments, the injection device is selected from a durable pen and a prefilled pen injection device. An example of a durable pen injection device is 4 or 5 (all from NovoNordisk A / S, Denmark). Examples of prefilled pen injection devices are (Novo Nordisk A / S, Denmark).
[0055] Indications
[0056] In some embodiments, the compositions of the present invention are used for medical purposes. In some embodiments, the compositions of the present invention can be used for the following medical treatments:
[0057] (i) prevention and / or treatment of all forms of diabetes, such as hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, non-insulin-dependent diabetes mellitus, MODY (maturity-onset diabetes of the young), gestational diabetes, and / or for the reduction of HbA1c;
[0058] (ii) delaying or preventing the progression of diabetes, such as the progression of type 2 diabetes, delaying the progression of impaired glucose tolerance (IGT) to insulin-requiring type 2 diabetes, and / or delaying the progression of insulin-not-requiring type 2 diabetes to insulin-requiring type 2 diabetes;
[0059] (iii) preventing and / or treating eating disorders, such as obesity, for example by reducing food intake, reducing body weight, suppressing appetite, inducing satiety; treating or preventing binge eating disorder, bulimia nervosa and / or obesity induced by antipsychotic or steroid administration; reducing gastric motility; and or delaying gastric emptying.
[0060] In some embodiments, the indication is (i). In some embodiments, the indication is (ii). In yet another specific aspect, the indication is (iii). In some embodiments, the indication is type 2 diabetes and / or obesity.
[0061] In some embodiments, the methods or uses include preventing, treating, reducing and / or inducing one or more diseases or conditions as defined herein. In some embodiments, the indications are (i) and (iii). In some embodiments, the indications are (ii) and (iii). In some embodiments, the invention includes administering an effective amount of a GLP-1 peptide. In some embodiments, the invention involves administering an effective amount of a GLP-1 peptide.
[0062] Generally, all subjects suffering from obesity are also considered to be overweight. In some embodiments, the present invention relates to methods for treating or preventing obesity. In some embodiments, the present invention relates to the use of the composition in treating or preventing obesity. In some embodiments, the subject suffering from obesity is a human, such as an adult or a pediatric patient (including infants, children and adolescents). Body mass index (BMI) is a measure of body fat based on height and weight. The calculation formula is BMI = weight in kilograms / height in meters 2 A human subject suffering from obesity may have a BMI of ≥30; the subject may also be referred to as obese. In some embodiments, a human subject suffering from obesity may have a BMI of ≥35 or a BMI in the range of ≥30 to <40. In some embodiments, the obesity is severe obesity or morbid obesity, wherein the human subject may have a BMI of ≥40.
[0063] In some embodiments, the present invention relates to a method for treating or preventing overweight, optionally in the presence of at least one weight-related comorbidity. In some embodiments, the present invention relates to the use of the composition, optionally in the presence of at least one weight-related comorbidity, for treating or preventing overweight. In some embodiments, the subject suffering from overweight is a human, such as an adult or a pediatric patient (including infants, children, and adolescents). In some embodiments, a human subject suffering from overweight may have a BMI of ≥25, such as a BMI of ≥27. In some embodiments, a human subject suffering from overweight has a BMI in the range of 25 to <30 or a BMI in the range of 27 to <30. In some embodiments, the weight-related comorbidity is selected from hypertension, diabetes (such as type 2 diabetes), dyslipidemia, high cholesterol, and obstructive sleep apnea.
[0064] In some embodiments, the present invention relates to methods of reducing weight. In some embodiments, the present invention relates to the use of the composition in reducing weight. A person experiencing weight loss according to the present invention may have a BMI of ≥25, such as a BMI of ≥27 or a BMI of ≥30. In some embodiments, a person experiencing weight loss according to the present invention may have a BMI of ≥35 or a BMI of ≥40. The term "weight loss" may include the treatment or prevention of obesity and / or overweight.
[0065] In some embodiments, as used herein, a specific value given with respect to a number or interval may be understood to be that specific value or approximately that specific value (eg, the specific value plus or minus 10%).
[0066] Embodiments of the present invention
[0067] The following are non-limiting embodiments of the present invention:
[0068] 1. A liquid pharmaceutical composition comprising semaglutide and not more than 0.01% (w / w) phenol.
[0069] 2. A liquid pharmaceutical composition comprising semaglutide and substantially free of phenol.
[0070] 3. The composition of embodiment 1 or 2, wherein the composition does not contain phenol.
[0071] 4. The composition according to any one of the preceding embodiments, wherein the composition is an aqueous solution comprising at least 60% w / w water, such as at least 70% w / w water or at least 80% w / w water.
[0072] 5. The composition according to any one of the preceding embodiments, wherein the concentration of semaglutide is 0.5-10 mg / ml of the composition.
[0073] 6. The composition according to any one of the preceding embodiments, wherein the semaglutide is in the form of a pharmaceutically acceptable salt.
[0074] 7. A composition according to any one of the preceding embodiments, wherein the composition comprises one or more pharmaceutically acceptable excipients.
[0075] 8. The composition according to any one of the preceding embodiments, wherein the composition comprises one or more agents for adjusting the pH, such as HCl, NaOH or acetate.
[0076] 9. The composition according to any one of the preceding embodiments, wherein the composition comprises a buffer and / or an isotonic agent.
[0077] 10. The composition according to any one of the preceding embodiments, wherein the buffer is present in a concentration of 0.01-50 mM relative to the composition.
[0078] 11. The composition according to any one of the preceding embodiments, wherein the buffer is a phosphate buffer.
[0079] 12. The composition according to any one of the preceding embodiments, wherein the phosphate buffer is selected from sodium dihydrogen phosphate, disodium hydrogen phosphate and sodium phosphate.
[0080] 13. A composition according to any one of the preceding embodiments, wherein the isotonic agent is present in a concentration of 8 mg / ml to 50 mg / ml, such as 14 mg / ml to 30 mg / ml of the composition.
[0081] 14. The composition according to any one of the preceding embodiments, wherein the isotonicity agent is propylene glycol.
[0082] 15. The composition according to any one of the preceding embodiments, wherein the composition does not contain a preservative.
[0083] 16. The composition according to any one of the preceding embodiments, wherein the pH of the composition is in the range of 6.0-10.0.
[0084] 17. A composition according to any one of the preceding embodiments, wherein the composition is for parenteral administration.
[0085] 18. A composition according to any one of the preceding embodiments, wherein the composition is for subcutaneous administration.
[0086] 19. A kit comprising a pharmaceutical composition as defined in any one of the preceding embodiments and instructions for use.
[0087] 20. A kit comprising a pharmaceutical composition as defined in any one of the preceding embodiments and an injection device for administering said composition to a subject, wherein said injection device is selected from the group consisting of a durable pen and a prefilled pen injection device.
[0088] 21. A pharmaceutical composition as described in any of the preceding embodiments for medical use.
[0089] 22. A pharmaceutical composition for use as described in any of the preceding embodiments for the treatment of diabetes or obesity.
[0090] 23. A method for preventing or treating diabetes or obesity, wherein a pharmaceutical composition as defined in any of the preceding embodiments is administered to a subject in need thereof. Example
[0091] General methods and characterization
[0092] Preparation of semaglutide composition:
[0093] Unless otherwise stated, the composition of semaglutide is prepared as follows: a buffer (e.g., sodium hydrogen phosphate dihydrate), an isotonic agent (e.g., propylene glycol), and an optional preservative (phenol) are dissolved in water. Semaglutide is dissolved therein, the pH is adjusted to 7.4 using sodium hydroxide and / or hydrochloric acid, and the composition is finally sterilized by filtering through a 0.22 μm sterile filter. Preparation of liraglutide composition:
[0094] Unless otherwise stated, the composition of liraglutide was prepared from solution 1 and solution 2: solution 1 was prepared by dissolving a buffer (sodium hydrogen phosphate dihydrate), an isotonic agent (mannitol) and an optional preservative (phenol) in water. Solution 2 was prepared by dissolving liraglutide under slow stirring. Solution 1 and solution 2 were mixed, the pH was adjusted to 8.15 using sodium hydroxide and / or hydrochloric acid, and the composition was finally sterilized by filtering through a 0.22 μm sterile filter.
[0095] Assay (I): Determination of the high molecular weight protein (HMWP) content of semaglutide compositions
[0096] The determination of HMWP content was performed using size exclusion chromatography (SE-HPLC) using a Waters Insulin HMWP column, a mobile phase of sodium chloride, sodium phosphate, phosphoric acid and isopropanol, isocratic elution, and detection at 280 nm. The content of HMWP is given as a percentage of the combined area of the chromatographic peak eluted earlier than the semaglutide monomer peak (i.e., the HMWP peak) relative to the total area of the HMWP and semaglutide monomer peaks.
[0097] Assay (II): Physical stability of semaglutide compositions assessed by ThT
[0098] The purpose of this assay is to evaluate the physical stability of GLP-1 peptides in aqueous solution.
[0099] The low physical stability of peptides or proteins can lead to the formation of amyloid fibrils. Fibrils are well-ordered filamentous macromolecular structures that are formed by the aggregation of soluble proteins and are mainly β-folded structures. Mature fibrils are insoluble and resistant to degradation. For the sake of drug product quality and patient safety, it is desirable to minimize and control the fibril formation events in the pharmaceutical compositions of therapeutic peptides and proteins. Protein aggregation, including fibril formation, can be assessed by visual inspection of samples. Fibrillar formation can be assessed by using thioflavin T (ThT), a small molecule indicator probe with high specificity for fibrils. Compared with ThT in solution, ThT has a unique fluorescence characteristic when combined with fibrils [Naiki et al. (1989) Anal. Biochem. 177, 244-249; LeVine (1999) Methods. Enzymol. 309, 274-284].
[0100] The formation of partially folded intermediates of the proposed peptide is the general initiation mechanism of fibril formation. A small amount of these intermediates nucleate to form a template, other intermediates can be assembled on this template, and fibril formation occurs. The lag time corresponds to the time interval of the core that generates a critical amount, and the apparent rate constant is the rate at which the fibril itself forms. Therefore, the lag time described in the ThT assay performed on the microplate reader is considered to indicate the fibril formation trend of the peptide composition in solution.
[0101] Before the assay, ThT was added to the sample from a stock solution in H2O to a final concentration of 20 μM in the sample. 200 μl of a sample aliquot of a composition comprising a GLP-1 peptide was placed in a 96-well microtiter plate (optical 0.4 mL black Thermo Scientific Nunc), with glass beads (2.8-3.2 mm, Whitehouse Scientific) placed in each well. Typically, eight replicates of each sample were placed on the plate. The plate was sealed with a sealing tape (Thermo Scientific Nunc).
[0102] Incubation, shaking and measurement of ThT fluorescence emission at a given temperature were performed in a BMG FLUOStar Omega or BMG FLUOStar Optima. The plate was incubated at 40°C under a double track shaking of 300rpm, 2mm amplitude. Fluorescence measurements were performed using excitation through a 450nm filter and measurement of emission through a 480nm filter. The plate was measured every 20 minutes for the desired length of time. Between each measurement, the plate was shaken and heated as described above.
[0103] The threshold was determined as the highest ThT fluorescence (in relative fluorescence units (RFU)) measured on the plate at a time of 1 hour 13 minutes, plus 100 RFU. The threshold was then used to calculate the lag time using the "time to threshold" method in the BMG FLUOstar software. Assay (III): Determination of liraglutide purity
[0104] Purity was determined by high performance liquid chromatography (HPLC) using a Waters XTerra TM MS C18 column, gradient elution with two mobile phases, one of which was aqueous ammonium phosphate buffer (pH 8) / acetonitrile mixture and the other was acetonitrile in water. Detection was performed at 215 nm.
[0105] Assay (IV): Determination of the sum of impurities of semaglutide
[0106] The purity of semaglutide was determined using reverse phase high performance liquid chromatography (RP-HPLC), using a Kinetex C18 column, isocratic elution followed by gradient elution with two mobile phases, one of which was an aqueous phosphate buffer / acetonitrile mixture and the other was an aqueous acetonitrile / isopropanol mixture. Detection was performed at 210 nm. The purity of semaglutide is given as the sum of impurities, expressed as the percentage of the combined area of all remaining chromatographic peaks relative to the semaglutide monomer peak.
[0107] Example 1: Semaglutide
[0108] Compositions comprising semaglutide were tested in this experiment. The compositions tested contained semaglutide (as shown in Table 1), propylene glycol (14 mg / ml), disodium hydrogen phosphate dihydrate (1.42 mg / ml) and optionally phenol (5.5 mg / ml) (as shown in Table 1), pH 7.4, in aqueous solution. These compositions were prepared as described in the "General Preparation Methods" section herein. The chemical stability expressed as HMWP was determined by the assay (I) described herein at the beginning of the experiment and after storage at 25°C, 30°C or 37°C. The physical stability expressed by the Thioflavin T (ThT) assay was determined by the assay (II) described herein.
[0109] The results are given in Tables 2 and 3. Surprisingly, these results show that the physical and chemical stability of semaglutide is improved in compositions without phenol relative to compositions containing phenol. The results shown in Table 3 are the average of the 8 samples tested.
[0110] Table 1. Compositions tested in Example 1
[0111]
[0112]
[0113] Table 2. Chemical stability of semaglutide compositions after storage at different temperatures, expressed as high molecular weight protein (HMWP) content. Lower HMWP concentrations correspond to better chemical stability.
[0114]
[0115] Table 3. Physical stability of semaglutide compositions as measured by the Thioflavin T (ThT) assay.
[0116] Longer lag times correspond to better physical stability.
[0117] Composition No. Lag time (hours) 5(phenol-free) >117 6 19 7(phenol-free) >117 8 35 9(phenol-free) >117 10 35
[0118] Example 2 (reference): Liraglutide
[0119] The results of Example 1 are also surprising in view of the fact that, in contrast to semaglutide, the GLP-1 compound liraglutide is less chemically stable in compositions that do not contain phenol. These results are shown in Table 5.
[0120] The results in Table 5 were obtained as follows: Compositions containing liraglutide were tested. The compositions tested contained liraglutide (as shown in Table 4), mannitol (36.9 mg / ml), disodium hydrogen phosphate (1.42 mg / ml) and optionally phenol (as shown in Table 4), pH 7.4, in aqueous solution. These compositions were prepared as described in the "General Preparation Methods" section herein. Chemical stability, expressed as purity, was determined by the assay (III) described herein at the beginning of the experiment and after storage at 25°C or 37°C.
[0121] Table 4. Compositions tested in Example 2
[0122] Composition No. describe 11 Liraglutide (3 mg / ml), phenol-free (pH 7.4) 12 Liraglutide (3 mg / ml), phenol (0.04 mg / ml) (pH 7.4) 13 Liraglutide (3 mg / ml), phenol (0.16 mg / ml) (pH 7.4) 14 Liraglutide (3 mg / ml), phenol (0.8 mg / ml) (pH 7.4) 15 Liraglutide (3 mg / ml), phenol (2.5 mg / ml) (pH 7.4)
[0123] Table 5. Chemical stability of compositions comprising liraglutide after storage at different temperatures, expressed as purity. Higher purity corresponds to better chemical stability.
[0124]
[0125] Example 3: Semaglutide - Additional Experiments
[0126] Compositions comprising semaglutide were tested in this experiment. The compositions tested contained semaglutide, an isotonic agent (propylene glycol (14 mg / ml) or sodium chloride (6.3 mg / ml)), an optional buffer (sodium dihydrogen phosphate dihydrate (1.42 mg / ml) or trisodium citrate dihydrate (2.35 mg / ml)) and optional phenol (5.5 mg / ml or 0.1 mg / ml), pH 7.0, 7.4 or 7.8, in aqueous solution; detailed information for each composition tested is shown in Table 6. These compositions were prepared as described in the "General Preparation Methods" section herein. At the beginning of the experiment and after storage at 30°C, the chemical stability expressed as HMWP was determined by assay (I), and the chemical stability expressed as the sum of impurities was determined by assay (IV) described herein. The physical stability expressed by the Thioflavin T (ThT) assay was determined by assay (II) described herein.
[0127] The results are given in Tables 7 and 8. Consistent with the results of Example 1, these results show that the physical and chemical stability of semaglutide is improved in compositions containing no phenol or containing low concentrations of phenol relative to compositions containing 5.5 mg / ml phenol. The results show that the physical and chemical stability of semaglutide is also improved in compositions containing no phenol that contain the buffer trisodium citrate dihydrate or that do not contain a buffer or isotonic agent sodium chloride relative to compositions containing phenol. The chemical and physical stability in compositions containing 0.1 mg / ml phenol is improved relative to compositions containing 5.5 mg / ml phenol, and similar to compositions containing no phenol. This is demonstrated by compositions with a pH of 7.0-7.8 and a semaglutide concentration of 0.1-10 mg / ml.
[0128] Table 6. Compositions tested in Example 3
[0129]
[0130]
[0131] *) Phos: disodium hydrogen phosphate dihydrate, 1.42 mg / ml. **) PG: propylene glycol, 14 mg / ml. ***) Citrate: trisodium citrate dihydrate, 2.35 mg / ml. # )None: No drug excipients added in the form of buffer. ## )NaCl: sodium chloride, 6.3 mg / ml.
[0132] Table 7. Chemical stability of semaglutide compositions after storage at 30° C., expressed as high molecular weight protein (HMWP) content and sum of impurities. Lower HMWP concentrations and sum of impurity concentrations correspond to better chemical stability.
[0133]
[0134]
[0135] DS: semaglutide. 1 Physically unstable at 30°C for >1 month.
[0136] Table 8. Physical stability of semaglutide compositions by Thioflavin T (ThT) assay.
[0137] Longer lag times correspond to better physical stability.
[0138] Composition No. Semaglutide (mg / ml) Phenol (mg / ml) Lag time (hours) 1(pH 7.0) 0.5 0 42 2(pH 7.0) 0.5 0.1 63 3(pH 7.0) 0.5 5.5 5 4 (pH 7.4) 0.5 0 >117 5(pH 7.4) 0.5 0.1 >117 6(pH 7.4) 0.5 5.5 87 7 (pH 7.8) 0.5 0 >117 8(pH 7.8) 0.5 0.1 >117 9(pH 7.8) 0.5 5.5 >117 10(pH 7.0) 10 0 117 11(pH 7.0) 10 0.1 >117 12(pH 7.0) 10 5.5 25 13(pH 7.4) 10 0 >117 14(pH 7.4) 10 0.1 >117 15(pH 7.4) 10 5.5 >117 16(pH 7.8) 10 0 >117 17(pH 7.8) 10 0.1 >117 18(pH 7.8) 10 5.5 >117 19 (low DS) 0.1 0 >117 20(Low DS) 0.1 5.5 >117 21(Citrate) 0.5 0 >117 22(Citrate) 0.5 5.5 >117 23 (without buffer) 0.5 0 >117 24 (without buffer) 0.5 5.5 4 25(NaCl) 0.5 0 >117 26(NaCl) 0.5 5.5 8
[0139] The results are the average of 8 samples tested. DS: Semaglutide
[0140] Although some features of the present invention have been described and illustrated herein, many modifications, substitutions, variations and equivalents will now occur to those skilled in the art. Therefore, it should be understood that it is intended to cover all these modifications and variations that fall within the true scope of the present invention with the attached implementation books.
Claims
1. A liquid pharmaceutical composition comprising semaglutide and no more than 0.01% (w / w) phenol, wherein the composition is an aqueous solution comprising at least 60% w / w water, and a. For parenteral administration; or b. further comprising one or more pharmaceutically acceptable excipients selected from a buffer or an isotonic agent, Furthermore, the pH of the composition is in the range of 6.5-8.5, such as pH 7.0-7.
8.
2. The composition of claim 1, wherein the composition does not contain phenol.
3. The composition according to any one of the preceding claims, wherein the concentration of semaglutide is 0.5-10 mg / ml or 0.01-5 mg / ml of the composition.
4. A composition according to any one of the preceding claims, wherein the composition comprises one or more pharmaceutically acceptable excipients.
5. A composition according to any one of the preceding claims, wherein the composition does not contain a preservative.
6. A composition according to any one of the preceding claims, wherein the composition is for parenteral administration.
7. The composition according to claim 6, wherein the parenteral administration is subcutaneous administration.
8. A kit comprising a liquid pharmaceutical composition comprising semaglutide and not more than 0.01% (w / w) phenol and instructions for use, wherein the liquid pharmaceutical composition is as defined in any one of claims 1 to 7.
9. A pharmaceutical composition as claimed in any one of the preceding claims 1 to 7 for medical use, such as for the treatment of diabetes or obesity.
10. The pharmaceutical composition according to the preceding claim 9, for use in a human subject suffering from overweight.
